The global histone deacetylase (HDAC) inhibitors market is expected to grow at a CAGR of 7.2% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing prevalence of chronic diseases and cancer, which are major drivers for the growth of this market.
The global histone deacetylase (HDAC) inhibitors market is segmented on the basis of type, application and region. On the basis of type, it is classified into fatty acid, hydroxamate, cyclic peptide and benzamide. On the basis of application it includes treatment for malignant tumors and chronic disease treatment. Geographically it covers North America, Latin America, Europe Asia Pacific and Middle East & Africa regions.
Some Of The Growth Factors Of This Market:
- Increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular diseases is driving the growth of the global Histone Deacetylase (HDAC) Inhibitors market.
- Increasing research and development activities in this field are also contributing to the growth of the global Histone Deacetylase (HDAC) Inhibitors market.
- The increasing number of new product launches in this field is also driving the growth of the global Histone Deacetylase (HDAC) Inhibitors market.
- The high cost associated with developing new drugs for chronic diseases such as cancer, diabetes, and cardiovascular diseases is restraining the growth of this market.
Industry Growth Insights published a new data on “Histone Deacetylase (HDAC) Inhibitors Market”. The research report is titled “Histone Deacetylase (HDAC) Inhibitors Market research by Types (Fatty Acid, Hydroxamate, Cyclic Peptide, Benzamide), By Applications (Treatment of Malignant Tumors, Chronic Disease Treatment, Others), By Players/Companies 4SC, Acetylon Pharmaceuticals, Celleron Therapeutics, Chipscreen Biosciences, Chroma Therapeutics, CrystalGenomics, Curis, MEI Pharma, Mirati Therapeutics, Novartis, Onxeo, Repligen, TetraLogic”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Histone Deacetylase (HDAC) Inhibitors Market Research Report
By Type
Fatty Acid, Hydroxamate, Cyclic Peptide, Benzamide
By Application
Treatment of Malignant Tumors, Chronic Disease Treatment, Others
By Companies
4SC, Acetylon Pharmaceuticals, Celleron Therapeutics, Chipscreen Biosciences, Chroma Therapeutics, CrystalGenomics, Curis, MEI Pharma, Mirati Therapeutics, Novartis, Onxeo, Repligen, TetraLogic
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
233
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
 Inhibitors Industry Outlook.svg)
Global Histone Deacetylase (HDAC) Inhibitors Market Report Segments:
The global Histone Deacetylase (HDAC) Inhibitors market is segmented on the basis of:
Types
Fatty Acid, Hydroxamate, Cyclic Peptide, Benzamide
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Treatment of Malignant Tumors, Chronic Disease Treatment, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- 4SC
- Acetylon Pharmaceuticals
- Celleron Therapeutics
- Chipscreen Biosciences
- Chroma Therapeutics
- CrystalGenomics
- Curis
- MEI Pharma
- Mirati Therapeutics
- Novartis
- Onxeo
- Repligen
- TetraLogic
 Inhibitors Market Overview.svg)
Highlights of The Histone Deacetylase (HDAC) Inhibitors Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Fatty Acid
- Hydroxamate
- Cyclic Peptide
- Benzamide
- By Application:
- Treatment of Malignant Tumors
- Chronic Disease Treatment
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Histone Deacetylase (HDAC) Inhibitors Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Inhibitors Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Histone deacetylase inhibitors (HDACIs) are a class of drugs that inhibit the activity of histone deacetylases. Histone deacetylases are enzymes that remove acetyl groups from histones, which can lead to changes in the structure and function of DNA. HDACIs have been shown to be effective in treating a variety of diseases, including cancer and Alzheimer's disease.
Some of the key players operating in the histone deacetylase (hdac) inhibitors market are 4SC, Acetylon Pharmaceuticals, Celleron Therapeutics, Chipscreen Biosciences, Chroma Therapeutics, CrystalGenomics, Curis, MEI Pharma, Mirati Therapeutics, Novartis, Onxeo, Repligen, TetraLogic.
The histone deacetylase (hdac) inhibitors market is expected to grow at a compound annual growth rate of 7.2%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Histone Deacetylase (HDAC) Inhibitors Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Histone Deacetylase (HDAC) Inhibitors Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Histone Deacetylase (HDAC) Inhibitors Market - Supply Chain
4.5. Global Histone Deacetylase (HDAC) Inhibitors Market Forecast
4.5.1. Histone Deacetylase (HDAC) Inhibitors Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Histone Deacetylase (HDAC) Inhibitors Market Size (000 Units) and Y-o-Y Growth
4.5.3. Histone Deacetylase (HDAC) Inhibitors Market Absolute $ Opportunity
5. Global Histone Deacetylase (HDAC) Inhibitors Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Histone Deacetylase (HDAC) Inhibitors Market Size and Volume Forecast by Type
5.3.1. Fatty Acid
5.3.2. Hydroxamate
5.3.3. Cyclic Peptide
5.3.4. Benzamide
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Histone Deacetylase (HDAC) Inhibitors Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Histone Deacetylase (HDAC) Inhibitors Market Size and Volume Forecast by Application
6.3.1. Treatment of Malignant Tumors
6.3.2. Chronic Disease Treatment
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Histone Deacetylase (HDAC) Inhibitors Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Histone Deacetylase (HDAC) Inhibitors Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Histone Deacetylase (HDAC) Inhibitors Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Histone Deacetylase (HDAC) Inhibitors Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Histone Deacetylase (HDAC) Inhibitors Demand Share Forecast, 2019-2026
9. North America Histone Deacetylase (HDAC) Inhibitors Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Histone Deacetylase (HDAC) Inhibitors Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Histone Deacetylase (HDAC) Inhibitors Market Size and Volume Forecast by Application
9.4.1. Treatment of Malignant Tumors
9.4.2. Chronic Disease Treatment
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Histone Deacetylase (HDAC) Inhibitors Market Size and Volume Forecast by Type
9.7.1. Fatty Acid
9.7.2. Hydroxamate
9.7.3. Cyclic Peptide
9.7.4. Benzamide
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Histone Deacetylase (HDAC) Inhibitors Demand Share Forecast, 2019-2026
10. Latin America Histone Deacetylase (HDAC) Inhibitors Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Histone Deacetylase (HDAC) Inhibitors Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Histone Deacetylase (HDAC) Inhibitors Market Size and Volume Forecast by Application
10.4.1. Treatment of Malignant Tumors
10.4.2. Chronic Disease Treatment
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Histone Deacetylase (HDAC) Inhibitors Market Size and Volume Forecast by Type
10.7.1. Fatty Acid
10.7.2. Hydroxamate
10.7.3. Cyclic Peptide
10.7.4. Benzamide
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Histone Deacetylase (HDAC) Inhibitors Demand Share Forecast, 2019-2026
11. Europe Histone Deacetylase (HDAC) Inhibitors Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Histone Deacetylase (HDAC) Inhibitors Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Histone Deacetylase (HDAC) Inhibitors Market Size and Volume Forecast by Application
11.4.1. Treatment of Malignant Tumors
11.4.2. Chronic Disease Treatment
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Histone Deacetylase (HDAC) Inhibitors Market Size and Volume Forecast by Type
11.7.. Fatty Acid
11.7.2. Hydroxamate
11.7.3. Cyclic Peptide
11.7.4. Benzamide
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Histone Deacetylase (HDAC) Inhibitors Demand Share, 2019-2026
12. Asia Pacific Histone Deacetylase (HDAC) Inhibitors Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Histone Deacetylase (HDAC) Inhibitors Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Histone Deacetylase (HDAC) Inhibitors Market Size and Volume Forecast by Application
12.4.1. Treatment of Malignant Tumors
12.4.2. Chronic Disease Treatment
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Histone Deacetylase (HDAC) Inhibitors Market Size and Volume Forecast by Type
12.7.1. Fatty Acid
12.7.2. Hydroxamate
12.7.3. Cyclic Peptide
12.7.4. Benzamide
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Histone Deacetylase (HDAC) Inhibitors Demand Share, 2019-2026
13. Middle East & Africa Histone Deacetylase (HDAC) Inhibitors Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Histone Deacetylase (HDAC) Inhibitors Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Histone Deacetylase (HDAC) Inhibitors Market Size and Volume Forecast by Application
13.4.1. Treatment of Malignant Tumors
13.4.2. Chronic Disease Treatment
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Histone Deacetylase (HDAC) Inhibitors Market Size and Volume Forecast by Type
13.7.1. Fatty Acid
13.7.2. Hydroxamate
13.7.3. Cyclic Peptide
13.7.4. Benzamide
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Histone Deacetylase (HDAC) Inhibitors Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Histone Deacetylase (HDAC) Inhibitors Market: Market Share Analysis
14.2. Histone Deacetylase (HDAC) Inhibitors Distributors and Customers
14.3. Histone Deacetylase (HDAC) Inhibitors Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. 4SC
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Acetylon Pharmaceuticals
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Celleron Therapeutics
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Chipscreen Biosciences
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Chroma Therapeutics
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. CrystalGenomics
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Curis
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. MEI Pharma
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Mirati Therapeutics
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Novartis
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Onxeo
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Repligen
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. TetraLogic
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
